Bristol-Myers Squibb dividend yield BMY
Dividends per share over the last twelve months divided by the share price, since 1972.
- Today, Nov 3, 2026
- 4.00%
- 10-year median
- 3.1%
- Against its 10-year history
- 72nd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 2.3% to 6.0%
- Peer median
- 2.2%
Bristol-Myers Squibb pays 4.00% of its share price in dividends over a year, as of Nov 3, 2026.
That is above its ten-year median of 3.1%, higher than on 72% of days in the last ten years.
Over that time it ranged from 2.3% in Feb 2018 to 6.0% in Jul 2024.
The median for 8 large drugmakers of a similar size is 2.2%.
Dividend yield over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.0% | 3.7% | 4.7% |
| 2025 | 4.5% | 4.0% | 5.7% |
| 2024 | 4.2% | 4.0% | 6.0% |
| 2023 | 4.4% | 2.9% | 4.6% |
| 2022 | 3.0% | 2.6% | 3.2% |
| 2021 | 3.1% | 2.8% | 3.5% |
| 2020 | 3.0% | 2.5% | 3.5% |
| 2019 | 2.6% | 2.6% | 3.8% |
| 2018 | 3.1% | 2.3% | 3.2% |
| 2017 | 2.5% | 2.4% | 3.2% |
| 2016 | 2.6% | 2.0% | 3.1% |
| 2015 | 2.2% | 2.1% | 2.6% |
| 2014 | 2.4% | 2.3% | 3.0% |
| 2013 | 2.6% | 2.6% | 4.1% |
| 2012 | 4.3% | 3.7% | 4.3% |
| 2011 | 3.7% | 3.7% | 5.1% |
| 2010 | 4.8% | 4.6% | 5.6% |
| 2009 | 5.0% | 4.8% | 6.8% |
| 2008 | 5.4% | 4.3% | 7.1% |
| 2007 | 4.1% | 3.5% | 4.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.
| Company | Dividend yield |
|---|---|
| BMYBristol-Myers Squibb | 4.00% |
| PFEPfizer | 5.57% |
| GILDGilead Sciences | 1.90% |
| AMGNAmgen | 2.13% |
| MRKMerck | 2.33% |
| BIIBBiogen | n/m |
| ABBVAbbVie | 2.39% |
| JNJJohnson & Johnson | 1.96% |
| JAZZJazz Pharmaceuticals | n/m |
| Peer median | 2.23% |
Where Bristol-Myers Squibb ranks
What the dividend yield tells you
Yearly dividends per share divided by the share price.
A yield that suddenly looks high often means the price fell because the dividend is at risk.
More on Bristol-Myers Squibb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.